hepatocellular carcinoma
Conditions
Interventions
experimental group (one-arm):Lenvatinib and Erlotinib
Sponsors
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Unlimited gender, aged 18-75 years; (2) Meets AASLD or EASL clinical diagnostic criteria of HCC; (3) Barcelona Clinic Liver Cancer (BCLC) Stage B or C, progressing after standard treatment; (4) Unresponsive or resistant to Lenvatinib; (5) EGFR target was positive in tumor tissues; (6) Measurable lesions (non lymph node lesions >= 1 cm, short diameter of lymph nodes >= 1.5 cm); (7) Child-Pugh A or scored 7 B; (8) Eastern Cooperative Oncology Group performance status score = 60 x 10^9/L, PT time extension <= 6 second.
Exclusion criteria
Exclusion criteria: (1) Uncorrectable coagulopathy with obvious bleeding tendency; (2) Patients need long-term anticoagulant or antiplatelet therapy; (3) Patients with unstable or active ulcer or gastrointestinal bleeding; (4) Heart disease requiring treatment or not well controlled high blood pressure; (5) Patients with interstitial pneumonia; (6) Hepatic encephalopathy or refractory ascites requiring treatment; (7) Other accompanying anti-tumor treatments; (8) The investigator assessed that the patient was unable or unwilling to comply with the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public Contactyaoping shi
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Outcome results
None listed